Portfolio

RiverVest Venture Partners® has funded 30 and exited or taken public 18 innovative life science companies.  Focusing primarily on the medical device and biopharmaceutical industries, RiverVest currently has assets under management of $250 million.

Accumetrics_150x150

Accumetrics, Inc., San Diego, CA

Merged with ITC Nexus Holding Company, renamed Accriva Diagnostics
Medical diagnostics company commercializing the VerifyNow®
System for the assessment of platelet function in patients taking
antiplatelet therapies.
PRIVATE

allakosblue

Allakos, Inc., San Carlos, CA

A biopharmaceutical company using engineered human antibodies to
target key effector cells in TH2-type immune responses.
PRIVATE

cgi_150x150

CGI Pharmaceuticals, Inc., Branford, CT

Acquired by Gilead Sciences, Inc. (GILD)
Biopharmaceutical company developing novel therapeutics targeting
protein kinases for cancer and autoimmune/inflammatory diseases.
ACQUIRED

Cabrellis2_150x150

Cabrellis Pharmaceuticals Corporation, San Diego, CA

Acquired by Pharmion Corporation (PHRM)
Specialty pharmaceutical company developing therapies
for the treatment of cancer.
ACQUIRED

Calypso_150x150

Calypso Medical Technologies, Inc., Seattle, WA

Acquired by Varian Medical Systems, Inc. (VAR)
Medical device company commercializing a proprietary
localization system to improve accuracy and management
of external beam radiation therapy.
ACQUIRED

Cameron_150x150

Cameron Health, Inc., San Clemente, CA

Acquired by Boston Scientific Corporation (BSX)
Medical device company developing a next-generation
implantable defibrillator that is easier to implant and
does not require leads that attach to the heart.
ACQUIRED

Centerre_150x150

Centerre Healthcare Corporation, Brentwood, TN

Healthcare services company developing and operating
inpatient rehabilitation facilities in partnership with
leading acute care hospitals.
PRIVATE

Conforma_150x150

Conforma Therapeutics Corporation, San Diego, CA

Acquired by Biogen Idec (BIIB)
Biotechnology company developing drugs that target a novel
pathway, HSP90 inhibition, for the treatment of cancer.
ACQUIRED

Cydex_150x150

CyDex Pharmaceuticals, Inc., Overland, KS

Acquired by Ligand Pharmaceuticals Incorporated (LGND)
Specialty pharmaceutical company commercializing a
proprietary technology that improves drug solubility.
ACQUIRED

Excaliard_150x150

Excaliard Pharmaceuticals, Inc., Carlsbad, CA

Acquired by Pfizer, Inc. (PFE)
Biopharmaceutical company focused on developing drugs
for the local treatment of fibrosis, including skin scarring.
ACQUIRED

Indev_150x150

IDev Technologies, Inc., Houston, TX

Acquired by Abbott Laboratories (ABT)
Medical device company commercializing a novel stent
for the treatment of peripheral vascular disease.
ACQUIRED

Kaperio_150x150

Kaperio, Inc., St. Louis, MO

Seed-stage biopharmaceutical company focused
on cardiovascular disease.
PRIVATE

Kereos_150x150

Kereos, Inc., St. Louis, MO

Biotechnology company developing site-targeted drugs
and molecular imaging agents for cancer
and cardiovascular disease.
PRIVATE

Lumena_150x150

Lumena Pharmaceuticals, Inc., San Diego, CA

Acquired by Shire plc (SHPG)
Biopharmaceutical company developing treatments for
metabolic diseases through non-systemically absorbed
compounds having targets within the lumen of the GI tract.
ACQUIRED

luminous_150x150

Luminous Medical, Inc., Carlsbad, CA

Medical device company developing an innovative automated
glucose measurement system to facilitate tight glycemic
control in hospital settings.
PRIVATE

Lutonix_150x150

Lutonix, Inc., Minneapolis, MN

Acquired by C.R. Bard, Inc. (BCR)
Medical device company developing drug-coated balloon catheters
for the treatment of vascular disease.
ACQUIRED

MacroGenics_150x150

MacroGenics, Inc., Rockville, MD

NASDAQ: MGNX
Leading antibody therapeutics company with a focus on
cancer and autoimmune diseases.
PUBLIC

Mpex_150x150

Mpex Pharmaceuticals, San Diego, CA

Acquired by Aptalis
Biopharmaceutical company developing an inhaled antibiotic
for the treatment of cystic fibrosis and chronic obstructive
pulmonary disease, and new therapies to combat the growing
issue of antibiotic resistance.
ACQUIRED

Neuros_150x150

Neuros Medical, Willoughby, OH

Medical device company developing neurostimulation therapies
for patients with chronic pain including neuroma/residual limb
pain with future applications in chronic post-surgical pain.
PRIVATE

Otonomy_150x150

Otonomy, Inc., San Diego, CA

NASDAQ: OTIC
Biopharmaceutical company developing novel drug therapies for
disorders of the inner and middle ear.
PUBLIC

Salient_150x150

Salient Surgical Technologies, Inc., Portsmouth, NH

Acquired by Medtronic, Inc. (MDT)
(Formerly TissueLink) Medical device company commercializing
innovative radio-frequency electrosurgical instruments for orthopedic,
spine, and general surgery.
ACQUIRED

Securus_150x150

Securus Medical Group, Inc., Cleveland, OH

Medical device company developing clinical tools to monitor
core body temperature within body cavities in order to avoid
thermal injury to the tissue due to energy from various sources.
PRIVATE

Tryton_150x150

Tryton Medical, Inc., Durham, NC

Medical device company commercializing novel stent systems
for the treatment of bifurcation lesions in coronary arteries.
PRIVATE

Velocimed_150x150

Velocimed, LLC, Minneapolis, MN

Acquired by St. Jude Medical, Inc. (STJ)
Leading medical device company developing endovascular
and cardiology-related technologies.
ACQUIRED

Xcyte_150x150

Xcyte Therapies, Inc., Seattle, WA

IPO, then acquired by Cyclacel Pharmaceuticals (CYCC)
Biotechnology company developing novel cell-based
immunotherapeutic treatments for cancer and infectious disease.
IPO

Xoft_150x150

Xoft, Inc., Fremont, CA

Acquired by iCAD, Inc. (ICAD)
Medical device company commercializing electronic, miniaturized
x-ray technology for use in radiation oncology.
ACQUIRED

ZSPharma_150X150

ZS Pharma, Inc., Ft. Worth, TX

NASDAQ: ZSPH
Biopharmaceutical company developing novel drug therapies
for hyperkalemia and other diseases.
PUBLIC

review of holosync meditation . research papers . DSL Verfügbarkeit